{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T22:21:55Z","timestamp":1794522115871,"version":"4.9.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022R1A2C2011122"],"award-info":[{"award-number":["2022R1A2C2011122"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Seoul National University","id":[{"id":"https:\/\/ror.org\/04h9pn542","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant treatment (NAT) is increasingly employed for pancreatic ductal adenocarcinoma (PDAC), necessitating reliable methods to assess tumor response. The College of American Pathologists (CAP) grading system is widely used to predict chemo-responsiveness and survival, but consensus on the most effective grading system and treatment regimen remains elusive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>This retrospective study included 462 patients with PDAC who underwent resection after NAT between 2009 and 2023. Survival outcomes were analyzed on the basis of CAP grades, and factors influencing favorable tumor responses were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients with CAP grades 0 and 1 showed significantly better overall survival (OS) and disease-free survival (DFS) than those with CAP grades 2 and 3. Key factors associated with improved outcomes included the 5-fluorouracil, irrinotecan, leucovorin, and oxaliplatin (FOLFIRINOX) regimen, stereotactic ablative body radiotherapy (SABR), and adjuvant chemotherapy. Despite achieving a pathological complete response, younger patients and those with pre-NAT suspected metastases were more prone to recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CAP grade is a strong prognostic tool for PDAC after NAT. Survival outcomes are enhanced by FOLFIRINOX, SABR, and adjuvant chemotherapy. Ongoing adjuvant therapy and monitoring are crucial for younger patients or those with pre-NAT metastasis. Further studies should refine tumor grading systems and explore objective post-NAT evaluation methods.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-025-18123-w","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T16:18:36Z","timestamp":1756225116000},"page":"9956-9965","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment according to CAP Grading System: Clinical Usefulness and Limitations"],"prefix":"10.1245","volume":"32","author":[{"given":"Go-Won","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younsoo","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inhyuck","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Soo","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Gun","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngmin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Sol","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Jae","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wooil","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Seong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3312-0503","authenticated-orcid":false,"given":"Jin-Young","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"issue":"7","key":"18123_CR1","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1245\/s10434-023-13353-2","volume":"30","author":"D Eshmuminov","year":"2023","unstructured":"Eshmuminov D, Aminjonov B, Palm RF, et al. FOLFIRINOX or gemcitabine-based chemotherapy for borderline resectable and locally advanced pancreatic cancer: a multi-institutional, patient-level, meta-analysis and systematic review. Ann Surg Oncol. 2023;30(7):4417\u201328.","journal-title":"Ann Surg Oncol."},{"issue":"18","key":"18123_CR2","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.3390\/cancers14184360","volume":"14","author":"HS Jung","year":"2022","unstructured":"Jung HS, Kim HS, Kang JS, et al. Oncologic benefits of neoadjuvant treatment versus upfront surgery in borderline resectable pancreatic cancer: a systematic review and meta-analysis. Cancers (Basel). 2022;14(18):4360.","journal-title":"Cancers (Basel)."},{"issue":"2","key":"18123_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","volume":"268","author":"JY Jang","year":"2018","unstructured":"Jang JY, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2\/3 trial. Ann Surg. 2018;268(2):215\u201322.","journal-title":"Ann Surg."},{"issue":"9","key":"18123_CR4","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/jhbp.648","volume":"26","author":"Y Byun","year":"2019","unstructured":"Byun Y, Han Y, Kang JS, et al. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. J Hepatobiliary Pancreat Sci. 2019;26(9):416\u201325.","journal-title":"J Hepatobiliary Pancreat Sci."},{"issue":"1","key":"18123_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41379-020-00683-9","volume":"34","author":"BV Janssen","year":"2021","unstructured":"Janssen BV, Tutucu F, van Roessel S, et al. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Mod Pathol. 2021;34(1):4\u201312.","journal-title":"Mod Pathol."},{"issue":"1","key":"18123_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/bjs\/znac350","volume":"110","author":"BV Janssen","year":"2022","unstructured":"Janssen BV, van Roessel S, van Dieren S, et al. Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). Br J Surg. 2022;110(1):67\u201375.","journal-title":"Br J Surg."},{"issue":"11","key":"18123_CR7","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1200\/JCO.21.02233","volume":"40","author":"E Versteijne","year":"2022","unstructured":"Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch Randomized PREOPANC trial. J Clin Oncol. 2022;40(11):1220\u201330.","journal-title":"J Clin Oncol."},{"key":"18123_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejrad.2018.04.024","volume":"104","author":"MA Bali","year":"2018","unstructured":"Bali MA, Pullini S, Metens T, et al. Assessment of response to chemotherapy in pancreatic ductal adenocarcinoma: comparison between diffusion-weighted MR quantitative parameters and RECIST. Eur J Radiol. 2018;104:49\u201357.","journal-title":"Eur J Radiol."},{"issue":"3","key":"18123_CR9","doi-asserted-by":"publisher","first-page":"730","DOI":"10.2214\/AJR.20.24567","volume":"217","author":"A Panda","year":"2021","unstructured":"Panda A, Garg I, Truty MJ, et al. Borderline resectable and locally advanced pancreatic cancer: FDG PET\/MRI and CT Tumor metrics for assessment of pathologic response to neoadjuvant therapy and prediction of survival. AJR Am J Roentgenol. 2021;217(3):730\u201340.","journal-title":"AJR Am J Roentgenol."},{"issue":"1","key":"18123_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00066-020-01654-4","volume":"197","author":"C Zimmermann","year":"2021","unstructured":"Zimmermann C, Distler M, Jentsch C, et al. Evaluation of response using FDG-PET\/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009\u2013011968-11). Strahlenther Onkol. 2021;197(1):19\u201326.","journal-title":"Strahlenther Onkol."},{"issue":"6","key":"18123_CR11","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1007\/s00330-021-08494-5","volume":"32","author":"HY Kim","year":"2022","unstructured":"Kim HY, Lee YJ, Chang W, et al. Tumor resectability and response on CT following neoadjuvant therapy for pancreatic cancer: inter-observer agreement study. Eur Radiol. 2022;32(6):3799\u2013807.","journal-title":"Eur Radiol."},{"issue":"12","key":"18123_CR12","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1002\/cncr.26651","volume":"118","author":"D Chatterjee","year":"2012","unstructured":"Chatterjee D, Katz MH, Rashid A, et al. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer. 2012;118(12):3182\u201390.","journal-title":"Cancer."},{"issue":"1","key":"18123_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/SLA.0000000000002672","volume":"268","author":"J He","year":"2018","unstructured":"He J, Blair AB, Groot VP, et al. Is a pathological complete response following neoadjuvant chemoradiation associated with prolonged survival in patients with pancreatic cancer? Ann Surg. 2018;268(1):1\u20138. https:\/\/doi.org\/10.1097\/SLA.0000000000002672.","journal-title":"Ann Surg."},{"issue":"11","key":"18123_CR14","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jamasurg.2017.2227","volume":"152","author":"JM Cloyd","year":"2017","unstructured":"Cloyd JM, Wang H, Egger ME, et al. Association of clinical factors with a major pathologic response following preoperative therapy for pancreatic ductal adenocarcinoma. JAMA Surg. 2017;152(11):1048\u201356.","journal-title":"JAMA Surg."},{"key":"18123_CR15","doi-asserted-by":"publisher","first-page":"117955492091940","DOI":"10.1177\/1179554920919402","volume":"14","author":"B Azab","year":"2020","unstructured":"Azab B, Macedo FI, Chang D, et al. The impact of prolonged chemotherapy to surgery interval and neoadjuvant radiotherapy on pathological complete response and overall survival in pancreatic cancer patients. Clin Med Insights Oncol. 2020;14:1179554920919402.","journal-title":"Clin Med Insights Oncol."},{"issue":"1","key":"18123_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.5009\/gnl20312","volume":"16","author":"S Ahn","year":"2022","unstructured":"Ahn S, Lee JC, Kim J, et al. Four-tier pathologic tumor regression grading system predicts the clinical outcome in patients who undergo surgical resection for locally advanced pancreatic cancer after neoadjuvant chemotherapy. Gut Liver. 2022;16(1):129\u201337.","journal-title":"Gut Liver"},{"issue":"3","key":"18123_CR17","doi-asserted-by":"publisher","first-page":"466","DOI":"10.5009\/gnl20070","volume":"15","author":"YJ Choi","year":"2021","unstructured":"Choi YJ, Byun Y, Kang JS, et al. Comparison of clinical outcomes of borderline resectable pancreatic cancer according to the neoadjuvant chemo-regimens: gemcitabine versus FOLFIRINOX. Gut Liver. 2021;15(3):466\u201375.","journal-title":"Gut Liver"},{"issue":"23","key":"18123_CR18","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.1002\/cncr.27636","volume":"118","author":"MH Katz","year":"2012","unstructured":"Katz MH, Fleming JB, Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118(23):5749\u201356.","journal-title":"Cancer"},{"issue":"1","key":"18123_CR19","doi-asserted-by":"publisher","first-page":"18278","DOI":"10.1038\/s41598-020-74067-z","volume":"10","author":"Y Matsuda","year":"2020","unstructured":"Matsuda Y, Ohkubo S, Nakano-Narusawa Y, et al. Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems. Sci Rep. 2020;10(1):18278.","journal-title":"Sci Rep"},{"issue":"10","key":"18123_CR20","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.3390\/biomedicines10102480","volume":"10","author":"P Burkon","year":"2022","unstructured":"Burkon P, Trna J, Slavik M, et al. Stereotactic body radiotherapy (SBRT) of pancreatic cancer\u2014a critical review and practical consideration. Biomedicines. 2022;10(10):2480.","journal-title":"Biomedicines"},{"key":"18123_CR21","doi-asserted-by":"publisher","first-page":"110064","DOI":"10.1016\/j.radonc.2023.110064","volume":"191","author":"MD Chuong","year":"2024","unstructured":"Chuong MD, Lee P, Low DA, et al. Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: a multi-center, open-label phase 2 study. Radiother Oncol. 2024;191:110064.","journal-title":"Radiother Oncol"},{"key":"18123_CR22","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/jhbp.12049","volume":"31","author":"HS Jung","year":"2024","unstructured":"Jung HS, Kwon W, Yun WG, et al. Optimal timing of surgery after neoadjuvant treatment in borderline resectable pancreatic cancer. J Hepatobiliary Pancreat Sci. 2024;31:737.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"18123_CR23","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1245\/s10434-024-16743-2","volume":"32","author":"WG Yun","year":"2025","unstructured":"Yun WG, Chae YS, Han Y, et al. Efficacy of neoadjuvant radiotherapy after chemotherapy and the optimal interval from radiotherapy to surgery for borderline resectable and resectable pancreatic cancer. Ann Surg Oncol. 2025;32:2819. https:\/\/doi.org\/10.1245\/s10434-024-16743-2.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"18123_CR24","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1245\/s10434-022-11451-1","volume":"29","author":"M Redegalli","year":"2022","unstructured":"Redegalli M, Schiavo Lena M, Cangi MG, et al. Proposal for a new pathologic prognostic index after neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma (PINC). Ann Surg Oncol. 2022;29(6):3492\u2013502. https:\/\/doi.org\/10.1245\/s10434-022-11451-1.","journal-title":"Ann Surg Oncol."},{"key":"18123_CR25","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1093\/ajcp\/aqae081","volume":"162","author":"A Dao","year":"2024","unstructured":"Dao A, Orr CE, Nyi Nyi MP, Wang T. Two-tier architecture-based grading for pancreatic cancer outperforms traditional grading. Am J Clin Pathol. 2024;162:623.","journal-title":"Am J Clin Pathol."},{"issue":"12","key":"18123_CR26","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1097\/PAS.0000000000000738","volume":"40","author":"SM Lee","year":"2016","unstructured":"Lee SM, Katz MH, Liu L, et al. Validation of a proposed tumor regression grading scheme for pancreatic ductal adenocarcinoma after neoadjuvant therapy as a prognostic indicator for survival. Am J Surg Pathol. 2016;40(12):1653\u201360.","journal-title":"Am J Surg Pathol."},{"key":"18123_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ejro.2016.06.003","volume":"3","author":"PV Foti","year":"2016","unstructured":"Foti PV, Privitera G, Piana S, et al. Locally advanced rectal cancer: qualitative and quantitative evaluation of diffusion-weighted MR imaging in the response assessment after neoadjuvant chemo-radiotherapy. Eur J Radiol Open. 2016;3:145\u201352.","journal-title":"Eur J Radiol Open."},{"issue":"3","key":"18123_CR28","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/SLA.0000000000005184","volume":"277","author":"TE Newhook","year":"2023","unstructured":"Newhook TE, Vreeland TJ, Griffin JF, et al. Prognosis associated with CA19-9 response dynamics and normalization during neoadjuvant therapy in resected pancreatic adenocarcinoma. Ann Surg. 2023;277(3):484\u201390. https:\/\/doi.org\/10.1097\/SLA.0000000000005184.","journal-title":"Ann Surg."},{"issue":"2","key":"18123_CR29","doi-asserted-by":"publisher","first-page":"107695","DOI":"10.1016\/j.ejso.2023.107695","volume":"50","author":"S Pollesel","year":"2024","unstructured":"Pollesel S, Lauretta A, Olivieri M, et al. Pre-treatment molecular profiling identifies predictive and prognostic fingerprints in locally advanced rectal cancer undergoing neoadjuvant chemoradiation: implications for treatment selection. Eur J Surg Oncol. 2024;50(2):107695.","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"18123_CR30","doi-asserted-by":"publisher","first-page":"100327","DOI":"10.1016\/j.modpat.2023.100327","volume":"36","author":"J Griem","year":"2023","unstructured":"Griem J, Eich ML, Schallenberg S, et al. Artificial intelligence-based tool for tumor detection and quantitative tissue analysis in colorectal specimens. Mod Pathol. 2023;36(12):100327.","journal-title":"Mod Pathol."},{"issue":"8","key":"18123_CR31","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.3390\/cancers15082365","volume":"15","author":"H Tada","year":"2023","unstructured":"Tada H, Gonda K, Kitamura N, Ishida T. Clinical significance of ABCG2\/BCRP quantified by fluorescent nanoparticles in breast cancer patients undergoing neoadjuvant chemotherapy. Cancers (Basel). 2023;15(8):2365.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"18123_CR32","first-page":"25","volume":"38","author":"C Shintia","year":"2016","unstructured":"Shintia C, Endang H, Diani K. Assessment of pathological response to neoadjuvant chemotherapy in locally advanced breast cancer using the Miller-Payne system and TUNEL. Malays J Pathol. 2016;38(1):25\u201332.","journal-title":"Malays J Pathol."}],"updated-by":[{"DOI":"10.1245\/s10434-026-20624-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000}}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18123-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18123-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18123-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:26:24Z","timestamp":1791491184000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18123-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":32,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["18123"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18123-w","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The approval number of the Institutional Review Board of Seoul National University Hospital was corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1245\/s10434-026-20624-1","URL":"https:\/\/doi.org\/10.1245\/s10434-026-20624-1","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}